Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Hemgenix (ETRANACOGENE DEZAPARVOVEC) in adults with severe or moderately severe hemophilia B
2024-510738-42-00Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Aug 2024
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoint: Annualized Bleeding Rate (ABR) non-inferiority comparison. Started Aug 2024; status: completed.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2024-510738-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510738-42-00.